The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 12, 2024
Filed:
Nov. 01, 2019
Applicant:
Bioinvent International Ab, Lund, SE;
Inventors:
Björn Frendéus, Lund, SE;
Ingrid Teige, Lund, SE;
Linda Mårtensson, Bjärred, SE;
Petra Holmkvist, Kävlinge, SE;
Monika Semmrich, Malmö, SE;
Assignee:
BIOINVENT INTERNATIONAL AB, Lund, SE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/283 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01);
Abstract
Described are novel antibody molecules that specifically bind to TNFR2 on a target cell and thereby agonize TNFR2, but that do not block the ligand TNF-α from binding to the TNFR2. Also described is the use of such antibody molecules in medicine, i.a, in treatment of cancer or chronic inflammatory diseases.